Epigenetic Remodeling Through GSK343-induced EZH2 Inhibition Alters SMYD2/SMYD3 Expression and Promotes Antitumor Effects.

Silva TAD, Fernandes EV, Bocchi M, Neto FSL, de Oliveira FM

Open source

DOI
10.1016/j.clbc.2026.07.028
Published
2026 Sep
Container
Clinical breast cancer
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.clbc.2026.07.028,
  title = {Epigenetic Remodeling Through GSK343-induced EZH2 Inhibition Alters SMYD2/SMYD3 Expression and Promotes Antitumor Effects.},
  author = {Silva TAD and Fernandes EV and Bocchi M and Neto FSL and de Oliveira FM},
  year = {2026},
  journal = {Clinical breast cancer},
  doi = {10.1016/j.clbc.2026.07.028},
  url = {https://doi.org/10.1016/j.clbc.2026.07.028}
}

RIS

TY  - JOUR
TI  - Epigenetic Remodeling Through GSK343-induced EZH2 Inhibition Alters SMYD2/SMYD3 Expression and Promotes Antitumor Effects.
AU  - Silva TAD
AU  - Fernandes EV
AU  - Bocchi M
AU  - Neto FSL
AU  - de Oliveira FM
PY  - 2026
JO  - Clinical breast cancer
DO  - 10.1016/j.clbc.2026.07.028
UR  - https://doi.org/10.1016/j.clbc.2026.07.028
ER  - 

APA

TAD, S., EV, F., M, B., FSL, N., & FM, D. O. (2026). Epigenetic Remodeling Through GSK343-induced EZH2 Inhibition Alters SMYD2/SMYD3 Expression and Promotes Antitumor Effects.. Clinical breast cancer. https://doi.org/10.1016/j.clbc.2026.07.028

Source records